NewsUnigene initiated with "market perform"
08/08/07 - Boenning & Scattergood
NEW YORK, August 8 (newratings.com) - Analyst Debjit Chattopadhyay of Boenning & Scattergood initiates coverage of Unigene Inc (UGNE) with a "market perform" rating.
In a research note dated August 7 and published this morning, the analyst mentions that the company has achieved significant success commercially with Fortical, its lead product for osteoporosis, which commands 46% market share domestically. The application of sCT in treating osteoarthritis could prove to be a blockbuster for the company, the analyst says. Novartis, Unigene’s partner, is carrying out two phase III trials for the evaluation of oral-sCT against osteoarthritis and osteoporosis, which is likely to have market potential worth billions of dollars, Boenning & Scattergood adds.